171 related articles for article (PubMed ID: 32805233)
41. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
42. Expression of Interactive Genes Associated with Apoptosis and Their Prognostic Value for Ovarian Serous Adenocarcinoma.
Shin K; Kim KH; Yoon MS; Suh DS; Lee JY; Kim A; Eo W
Adv Clin Exp Med; 2016; 25(3):513-21. PubMed ID: 27629740
[TBL] [Abstract][Full Text] [Related]
43. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
44. S100A4 interacts with p53 in the nucleus and promotes p53 degradation.
Orre LM; Panizza E; Kaminskyy VO; Vernet E; Gräslund T; Zhivotovsky B; Lehtiö J
Oncogene; 2013 Dec; 32(49):5531-40. PubMed ID: 23752197
[TBL] [Abstract][Full Text] [Related]
45. The C-terminal region of S100A4 is important for its metastasis-inducing properties.
Zhang S; Wang G; Liu D; Bao Z; Fernig DG; Rudland PS; Barraclough R
Oncogene; 2005 Jun; 24(27):4401-11. PubMed ID: 15856021
[TBL] [Abstract][Full Text] [Related]
46. Nonmuscle myosin IIA and IIB differentially modulate migration and alter gene expression in primary mouse tumorigenic cells.
Halder D; Saha S; Singh RK; Ghosh I; Mallick D; Dey SK; Ghosh A; Das BB; Ghosh S; Jana SS
Mol Biol Cell; 2019 Jun; 30(12):1463-1476. PubMed ID: 30995168
[TBL] [Abstract][Full Text] [Related]
47. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
[TBL] [Abstract][Full Text] [Related]
48. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
[TBL] [Abstract][Full Text] [Related]
49. Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer.
Nunes M; Pacheco F; Coelho R; Leitão D; Ricardo S; David L
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162954
[TBL] [Abstract][Full Text] [Related]
50. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4).
Rodrigues MA; Gomes DA; Cosme AL; Sanches MD; Resende V; Cassali GD
Biomed Pharmacother; 2022 Jan; 145():112403. PubMed ID: 34798470
[TBL] [Abstract][Full Text] [Related]
51. Downregulation of non‑muscle myosin IIA expression inhibits migration and invasion of gastric cancer cells via the c‑Jun N‑terminal kinase signaling pathway.
Liu T; Ye Y; Zhang X; Zhu A; Yang Z; Fu Y; Wei C; Liu Q; Zhao C; Wang G
Mol Med Rep; 2016 Feb; 13(2):1639-44. PubMed ID: 26719067
[TBL] [Abstract][Full Text] [Related]
52. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
53. Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.
Yang Y; Zhang J; Zhu Y; Zhang Z; Sun H; Feng Y
Int J Gynecol Cancer; 2014 Nov; 24(9):1564-74. PubMed ID: 25340291
[TBL] [Abstract][Full Text] [Related]
54. Structure of Ca2+-bound S100A4 and its interaction with peptides derived from nonmuscle myosin-IIA.
Malashkevich VN; Varney KM; Garrett SC; Wilder PT; Knight D; Charpentier TH; Ramagopal UA; Almo SC; Weber DJ; Bresnick AR
Biochemistry; 2008 May; 47(18):5111-26. PubMed ID: 18410126
[TBL] [Abstract][Full Text] [Related]
55. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS
Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389
[TBL] [Abstract][Full Text] [Related]
56.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
57. Cysteine 81 is critical for the interaction of S100A4 and myosin-IIA.
Dulyaninova NG; Hite KM; Zencheck WD; Scudiero DA; Almo SC; Shoemaker RH; Bresnick AR
Biochemistry; 2011 Aug; 50(33):7218-27. PubMed ID: 21749055
[TBL] [Abstract][Full Text] [Related]
58. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
59. Structure of the S100A4/myosin-IIA complex.
Ramagopal UA; Dulyaninova NG; Varney KM; Wilder PT; Nallamsetty S; Brenowitz M; Weber DJ; Almo SC; Bresnick AR
BMC Struct Biol; 2013 Nov; 13():31. PubMed ID: 24252706
[TBL] [Abstract][Full Text] [Related]
60. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
